All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can Isa-KRd achieve deep responses in high-risk NDMM, regardless of transplant eligibility?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Katja Weisel, University Medical Center of Hamburg - Eppendorf, Hamburg, DE. We asked, Can Isa-KRd (isatuximab, carfilzomib, lenalidomide, and dexamethasone) achieve deep responses in high-risk newly diagnosed multiple myeloma, regardless of transplant eligibility?

In this video, Weisel discusses the updated interim analysis data from the GMMG-CONCEPT trial (NCT03104842) evaluating the induction, consolidation, and maintenance treatment with Isa-KRd.

 

Share: